BI
GPCR icon

BVF Inc’s Structure Therapeutics GPCR Stock Holding History

BVF Inc’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$181M Sell
3,366,823
-92,535
-3% -$4.09M 4.62% 6
2026
Q1 		$167M Sell
3,459,358
-19,664
-0.6% -$1.35M 5.31% 5
2025
Q4 		$242M Buy
3,479,022
+275,105
+9% +$11.2M 8.15% 4
2025
Q3 		$89.7M Buy
3,203,917
+1,432,500
+81% +$28.5M 3.64% 9
2025
Q2 		$36.7M Hold
1,771,417
– – 1.31% 18
2025
Q1 		$30.7M Hold
1,771,417
– – 1.25% 18
2024
Q4 		$48M Sell
1,771,417
-467,569
-21% -$16.6M 1.63% 15
2024
Q3 		$98.3M Sell
2,238,986
-248,776
-10% -$9.62M 2.87% 7
2024
Q2 		$97.7M Buy
2,487,762
+1,674,774
+206% +$68.8M 2.74% 10
2024
Q1 		$34.8M Hold
812,988
– – 0.96% 29
2023
Q4 		$33.1M Sell
812,988
-937,012
-54% -$53.7M 0.83% 29
2023
Q3 		$88.2M Hold
1,750,000
– – 2.38% 11
2023
Q2 		$72.7M Hold
1,750,000
– – 2.03% 12
2023
Q1 		$41.6M Buy
+1,750,000
New +$41.1M 1.52% 21

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BVF Inc's GPCR Position: Q2 2026 in Review

BVF Inc reduced its Structure Therapeutics (GPCR) stake by 2.7% in Q2 2026, selling an estimated $4.09M and leaving 3,366,823 shares worth $181M. The position accounts for 4.62% of the portfolio, ranked #6.

BVF Inc first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $242M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • BVF Inc held 3,366,823 shares of Structure Therapeutics worth $181M as of Q2 2026.
  • BVF Inc sold 92,535 Structure Therapeutics shares in Q2 2026, an estimated $4.09M.
  • Structure Therapeutics made up 4.62% of BVF Inc's portfolio in Q2 2026, its #6 holding.
  • BVF Inc first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • BVF Inc's Structure Therapeutics position peaked at $242M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.